Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of GSK’s Requip (ropinirole), marking the first generic approval for this medication in China. The drug is indicated for the treatment of Parkinson’s disease (PD) and PD with non-motor symptoms.
Parkinson’s disease is a prevalent neurodegenerative disorder among the elderly, characterized by resting tremors, muscle rigidity, bradykinesia, and cognitive decline. The condition progressively worsens, imposing significant burdens on patients and their families. Ropinirole, a novel dopamine receptor agonist, penetrates the central nervous system and targets postsynaptic dopamine receptors, alleviating symptoms such as bradykinesia, limb tremors, and muscle tension. It has become a standard treatment for Parkinson’s disease.
Requip was originally approved in the US and China in 2009 and 2022, respectively. Huahai Pharma’s generic version received marketing approval in the US in May 2022.- Flcube.com
